Catalyst pharmaceuticals stock forecast
What are analysts' target prices for Catalyst Pharmaceuticals' stock? Three stock analysts have posted 12-month price targets for Catalyst Pharmaceuticals stock. Your forecast varies between $ and $. On average, they expect Catalyst Pharmaceuticals' stock price to hit $100 next year.
What is the upside for Catalyst Pharmaceuticals' stock?
On average, they expect Catalyst Pharmaceuticals' stock price to hit $1 next year. This indicates a possible rise in the current share price. Check out analyst price targets for the top rated stocks of Catalyst Pharmaceuticals or Wall Street Analysts.
Is Catalyst Pharmaceuticals (cprx) stock a buy or sell?
Based on the ratings provided by 3 analysts in the past year, the consensus rating for the stock is Catalyst Pharmaceuticals Buy, based on the current 3 buy ratings for CPRX. The 12-month average target price for Catalyst Pharmaceuticals is $ with a high target of $ and a low target of $ .
What is the marketbeat consensus rating for Catalyst Pharmaceuticals?
The consensus score of Catalyst Pharmaceuticals is equal to the average consensus score of healthcare companies. Learn more Do MarketBeat users love Catalyst Pharmaceuticals more than their competitors?
What is the price targets for Catalyst Pharmaceuticals?
The 12-month average target price for Catalyst Pharmaceuticals is $ with a high $ target and a low $ target. Learn More Do Wall Street Analysts Think Catalyst Pharmaceuticals Outperforms Its Competitors?
When will Catalyst Pharmaceuticals release its next quarterly earnings?
Catalyst Pharmaceuticals plans to release its next quarterly report on Monday, November 8, 2021. View Catalyst Pharmaceuticals' earnings forecast.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
How has covid-19 affected catcatalyst Pharmaceuticals' stock?
Shares of Catalyst Pharmaceuticals traded at $11 in March 2020 as COVID19 (coronavirus) reached pandemic status, according to the World Health Organization (WHO). Since then, CPRX stocks have risen and are now trading in dollars. Find out which stocks have been most affected by COVID19.
Where is Catalyst Pharmaceuticals located?
Catalyst Pharmaceuticals is headquartered at 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. How can I contact Catalyst Pharmaceuticals? Catalyst Pharmaceuticals Postal Address: 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134.
Should you buy Catalyst Pharmaceuticals (cat) stock?
Wall Street stock analysts agree that investors should buy Catalyst Pharmaceuticals. Browse analyst ratings for Catalyst Pharmaceuticals or major stocks. Which MarketBeat Stock Does Catalyst Pharmaceuticals Prefer?
![:eight_spoked_asterisk:]( ":eight_spoked_asterisk:")
What is the upside for catalyst pharmaceuticals' stock exchange
Wall Street analysts' average price targets point to upside potential for Catalyst (CPRX). While the effectiveness of this much-requested statistic is questionable, Zacks Investment Research Catalysts (CPRX) bullish Q3 earnings beat estimates from 3 weeks ago.
Should you avoid Catalyst Pharmaceuticals (cat) stock?
Shares of Catalyst Pharmaceuticals show several negative signals and despite the positive dynamics, they believe Catalyst Pharmaceuticals will show poor results in the coming days or weeks. That's why they have a negative rating for this promotion.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
What is the price of cprx stock?
CPRX shares can currently be bought for about $1. How much money does Catalyst Pharmaceuticals make? Catalyst Pharmaceuticals has a market cap in the millions of dollars and generates millions of dollars in annual revenue.
Is Catalyst Pharmaceuticals (cprx) stock set for an inline return?
Zack's own data shows that Catalyst Pharmaceuticals, Inc. currently ranks third on Zacks and they expect CPRX stock to perform in line with the market in the coming months.
Is catcatalyst (cprx) a good stock to buy?
Catalyst (CPRX) has maintained its recent price action and could suit investors looking to take advantage of stocks that are currently in flux.
What is Catalyst Pharmaceuticals Inc (C catalyst)?
Click here for the best stock market tips, every day for free! Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, develops and markets therapies for people with debilitating rare diseases.
![:brown_circle:]( ":brown_circle:")
Who owns Catalyst Pharmaceuticals stock?
Company members who own stock in Catalyst Pharmaceuticals include Alicia Grande, Charles B. Okeefe, Gary Ingenito, Patrick J. Mackenany, Philip H. Coelho and Steve Miller. Discover institutional ownership trends for Catalyst Pharmaceuticals.
Does Catalyst Pharmaceuticals stock hold sell signals?
Shares of Catalyst Pharmaceuticals contain short- and long-term moving average selling signals, putting a more negative outlook for the stock. The upward correction will find some resistance near the $ and $ lines.
Is catalyst pharmaceuticals (cprx) stock a buy or sell 2020
Based on the ratings provided by 3 analysts in the past year, the consensus rating for the stock is Catalyst Pharmaceuticals Buy, based on the current 3 buy ratings for CPRX. The 12-month average target price for Catalyst Pharmaceuticals is $ with a high $ target and a low $ target.
![:brown_circle:]( ":brown_circle:")
How does Catalyst Pharmaceuticals's stock compare to other medical stocks?
MarketBeat users like Catalyst Pharmaceuticals own more shares than other healthcare companies. MarketBeat users gave Catalyst Pharmaceuticals the highest rating, while healthcare companies received an average rating of excellence from MarketBeat users. Does the Catalyst Pharmaceuticals stock price have many advantages?
How does marketbeat calculate consensus analyst ratings?
MarketBeat calculates analyst consensus scores for a stock based on the most recent rating of any Wall Street analyst who has reviewed the stock in the past 12 months. Each analyst's rating is normalized to a standard rating score of 1 (sell), 2 (hold), 3 (buy), or 4 (buy strong).
What is the marketbeat consensus rating for catalyst pharmaceuticals scam
Four stock analysts gave the stock a buy recommendation. According to Catalyst Pharmaceuticals, the consensus rating is currently "buy" and the average price target is $. Shares of Catalyst Pharmaceuticals opened Monday at $100.
![:brown_circle:]( ":brown_circle:")
Do analysts like Catalyst Pharmaceuticals stock more than its medical competitors?
Analysts like Catalyst Pharmaceuticals have more shares than other healthcare companies. The consensus score of Catalyst Pharmaceuticals is equal to the average consensus score of healthcare companies.
![:brown_circle:]( ":brown_circle:")
What are the divisions of Roche Holding AG?
Roche Holding AG is engaged in health research. It operates through the following business segments: Pharmaceuticals and Diagnostics. The pharmaceutical division includes business segments such as Roche Pharma and Chuga.
Should biotechs reap millions from New Roche collaboration?
The biotech will receive hundreds of millions of dollars from a new partnership with a leading pharmaceutical company. Roche and its Genentech innovation division have a long history of successfully developing cancer treatments, and Roche's pipeline is full of new candidates.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
How did Roche's cancer drugs perform in 2019?
Roche relied on three cancer drugs, Rituxan, Avastin and Herceptin, which accounted for 32% of sales in 2019. The launch of biosimilars for all three drugs had a strong impact on sales in 2020.
![:brown_circle:]( ":brown_circle:")
What are the business areas of Roche Diagnostics?
The diagnostic business consists of the following four business segments: core and point-of-care solutions, molecular diagnostics, tissue diagnostics and diabetes management. The company was founded on October 1, 1896 by Fritz Hoffmann La Roche and is headquartered in Basel, Switzerland.
![:brown_circle:]( ":brown_circle:")
What are Catalyst Pharmaceuticals's earnings expected to grow next year?
Catalyst Pharmaceuticals earnings are expected to rise from $/share to $/share next year, marking an increase. Check out the latest news, bid/ask prices, SEC filings and insider trading for your stocks.
What is Catalyst Pharmaceuticals's PE (price to earnings) ratio?
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has a lagging P/E ratio that is a multiple and a P/E ratio that is a multiple. What is Catalyst Pharmaceuticals' EPS forecast for the coming year?
Does Catalyst Pharmaceuticals have what it takes to outperform?
While there's no way to know for sure if a particular stock has the potential to outperform it, analyzing the company's future catalysts is one piece of advice that can help you tip the game in your favor. Catalyst Pharmaceuticals (NASDAQ:CPRX) makes a drug called Firdapse to treat Lambert-Eaton myasthenia syndrome (LEMS), a rare autoimmune disease.
What is the Catalyst Pharmaceuticals stock forecast for 2022?
Catalyst Pharmaceuticals' inventory forecast is quoted in US dollars as of September 5, 2022, Monday, and in US dollars as of September 5, 2026, Saturday. Catalyst Pharmaceuticals Stock Forecasts, CPRX Price Forecasts: Buy or Sell Catalyst Pharmaceuticals, Inc. Stock? The cost of CPRX for today is USD.
Is Catalyst Pharmaceuticals (cprx) stock in an uptrend?
As of September 5, 2021, CPRX's current share price on Sunday is $$ and the data shows the asset price has been rising for 1 year (or since inception). Catalyst Pharmaceuticals' stock price is on an upward trend, leading them to believe that comparable market segments were very popular during this period.
